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Circulating immunoglobulins including immunoglobulin G (IgG) and IgM play a critical 
role in the immune homeostasis by modulating functions of immune cells. These func-
tions are mediated in part by natural antibodies. However, despite being second most 
abundant antibody in the circulation, the immunoregulatory function of IgA is relatively 
unexplored. As Th17 cells are the key mediators of a variety of autoimmune, inflamma-
tory, and allergic diseases, we investigated the ability of monomeric IgA (mIgA) isolated 
from pooled plasma of healthy donors to modulate human Th17 cells. We show that 
mIgA inhibits differentiation and amplification of human Th17 cells and the production 
of their effector cytokine IL-17A. mIgA also suppresses IFN-γ responses under these 
experimental conditions. Suppressive effect of mIgA on Th17 responses is associated 
with reciprocal expansion of FoxP3-positive regulatory T cells. The effect of mIgA on 
Th17 cells is dependent on F(ab′)2 fragments and independent of FcαRI (CD89) and 
DC-SIGN. Mechanistically, the modulatory effect of mIgA on Th17  cells implicates 
suppression of phosphorylation of signal transducer and activator of transcription 
3. Furthermore, mIgA binds to CD4+ T  cells and recognizes in a dose-dependent 
manner the receptors for cytokines (IL-6Rα and IL-1RI) that mediate Th17 responses. 
Our findings thus reveal novel anti-inflammatory functions of IgA and suggest potential 
therapeutic utility of mIgA in autoimmune and inflammatory diseases that implicate 
Th17 cells.
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inTrODUcTiOn
CD4+ T-helper (Th) cells play an important role in the immune responses against both pathogens 
and self-antigens. Based on distinct cytokine and transcription factor profiles, several subsets of 
CD4+ Th cells have been elucidated. These include Th1, Th2, and CD4+CD25+ regulatory T cells 
(Tregs). In addition, Th17 cells that are characterized by lineage-specific transcription factor retinoic 
acid-related orphan receptor C (RORC) and the secretion of signature cytokine IL-17A are also 
identified (1). Phosphorylation of signal transducer and activator of transcription 3 (STAT3) is 
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essential for the differentiation and amplification of Th17 cells. 
Th17  cells have been shown to play an important role in the 
defense against extracellular pathogens and in the pathogenesis 
of a variety of autoimmune, inflammatory, and allergic diseases 
(1, 2). Therefore, modulation of Th17 responses represents one of 
the fast evolving therapeutic options for the treatment of autoim-
mune and systemic inflammatory diseases.
Immunoglobulin A (IgA) is the most prevalent antibody 
at mucosal sites and the second most abundant antibody in 
the circulation. Secretory IgA at mucosal sites is dimeric in 
nature. It has been proposed that high affinity secretory IgA 
prevents mucosal colonization of invading pathogens and low 
affinity secretory IgA regulates commensal bacteria (3, 4). In the 
circulation, IgA is mostly monomeric although nearly 10–20% 
of circulating IgA are presented as dimeric or polymeric in 
nature (5). Currently, three bona fide receptors have been 
identified for IgA. FcαRI (CD89) expressed on various innate 
cells such as monocytes, macrophages, dendritic cells (DCs), 
and neutrophils is specific for IgA and mediates effector func-
tions of IgA. The other two receptors, polymeric Ig receptor 
and Fcα/μR recognize both IgA and IgM and are therefore not 
specific for IgA. In addition to the aforementioned receptors, two 
alternative IgA receptors have also been identified. They are the 
asialoglycoprotein receptor that is implicated in the catabolism 
of IgA, and the transferrin receptor that mediates deposition 
of IgA in tissues (6).
Although triggering of FcαRI by IgA immune complexes or 
polymers induces activation of immune cells (7–9) via com-
plete phosphorylation of tyrosine residues of immunoreceptor 
tyrosine-based activation motif (ITAM) within the associated 
FcRγ adaptors, naturally occurring monomeric IgA (mIgA) in 
the plasma was found to exert inhibitory effects on the activation 
of immune cells by triggering inhibitory ITAM (ITAMi) signaling 
through the associated FcRγ chain and recruitment of tyrosine 
phosphatase Src homology 2 domain-containing phosphatase-1 
(SHP-1) (10–13). mIgA also induces death in activated neu-
trophils (14) and inhibits complement deposition mediated by 
anti-ganglioside antibodies (15). The anti-inflammatory effects 
of mIgA have been explored in various experimental models 
(10–13, 16).
Thus, so far anti-inflammatory effects of mIgA have been elu-
cidated mainly in the context of innate immune cells and FcαRI. It 
is not known whether anti-inflammatory effects of mIgA observed 
in various experimental models are solely due to the modulation 
of innate cells or also due to anti-inflammatory effects on the 
cells of adaptive immune compartment and particularly CD4+ 
T cells that are critical players in the pathogenesis of autoimmune 
and inflammatory diseases. Therefore, in view of emerging roles 
of Th17  cells in the pathogenesis of autoimmune, allergy, and 
inflammatory diseases, we explored the immunomodulatory role 
of mIgA isolated from the pooled plasma of healthy donors on 
the human Th17 cell differentiation, amplification, and secretion 
of effector cytokine IL-17A. Our data indicate that mIgA binds 
to CD4+ T cells independent of FcαRI (CD89), and reciprocally 
regulates human Th17 and FoxP3-positive Treg cells. The effect 
of mIgA on Th17  cells is dependent on F(ab′)2 fragments and 
implicates suppression of phosphorylation of STAT3. Our data 
thus reveal FcαRI-independent immunomodulatory functions 
of naturally occurring mIgA and potential therapeutic utility of 
mIgA in autoimmune and inflammatory diseases that implicate 
Th17 cells.
MaTerials anD MeThODs
cell-culture reagents and antibodies
Anti-CD3 (clone UCHT1), anti-CD28 mAbs (clone 37407), and 
TGF-β1 were procured from R&D Systems (Lille, France). IL-1β, 
IL-6, and IL-21 were purchased from Immuno Tools (Friesoythe, 
Germany). Plasma-derived human serum albumin (HSA) was 
from Laboratoire Française de Biotechnologies (Les Ulis, France).
immunoglobulins
Monomeric IgA and F(ab′)2 fragments of mIgA and IVIG 
(Privigen®) were provided by CSL Behring AG (Bern, Switzerland).
Monomeric IgA was derived from the AIEX chromatographic 
step of the IVIG manufacture process of CSL Behring AG. 
Fraction F4 was obtained after a post-wash of the Macro-Prep 
High Q (BioRad, Hercule, CA, USA) column with 10  mM 
phosphate/30  mM acetate at pH 6.5 by elution with 55  mM 
tartrate/5 mM acetate at pH 7.6. Fraction F4 was then brought 
to approximately 1 mg/ml in PBS by ultra-/diafiltration and then 
depleted of IgG by affinity chromatography using an IgSelect 
resin (GE Healthcare, Glattbrugg, Switzerland). mIgA was 
directly harvested from the flow through fraction of the IgSelect 
chromatography and brought to its final formulation via ultra-/
diafiltration of 48.5 g/l in PBS.
F(ab′)2 fragments from IgA were generated by solid phase 
pepsin digestion using pepsin-coupled beads (Thermo Fisher 
Scientific, Allschwil, Switzerland). The F(ab′)2 fragments 
were recovered by centrifugation. The supernatant was sterile 
filtered (0.45  μm) and formulated in PBS using ultrafiltration 
centrifugal devices (30,000 Da MWCO; Sartorius, Tagelswangen, 
Switzerland). Purity and integrity were controlled by SDS-PAGE 
and SE chromatography.
The labeling of mIgA and IVIG was done with the Lightning-
Link® Rapid DyLight® 650 kit (Innova Biosciences, Cambridge, 
UK) according to manufacturer’s instructions.
cell Purification
Buffy coats from the healthy donors were processed to purify 
peripheral blood mononuclear cells (PBMCs). Ethics committee 
approval for the use of such material (Institut National de la Santé 
et de la Recherche-EFS ethical committee convention 15/EFS/012) 
was obtained and experiments were performed in accordance 
with the approved guidelines of INSERM. The CD4+ T cell isola-
tion kit-II (Miltenyi Biotec, Paris, France) was used to isolate 
untouched total CD4+ T cells by negative selection. Subsequently, 
CD45RA+ and CD45RO+ CD4+ T cells were separated by using 
CD45RO microbeads (Miltenyi Biotec). Furthermore, CD25+ 
cells were depleted from the CD45RA+ fraction by using CD25 
microbeads (Miltenyi Biotec) to obtain CD4+CD25−CD45RO− 
naïve T cells. The purity of all subpopulations was more than 96%.
Monocytes were isolated from PBMC by using CD14 
microbeads (Miltenyi Biotec) and were cultured for 5  days 
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with GM-CSF (1,000 IU/million cells) and IL-4 (500 IU/mil-
lion cells) (both from Miltenyi Biotec) for the differentiation 
into DCs (17).
T-cell stimulation and culture
Forty-eight well flat bottom plates were coated with 1.5 μg/ml 
anti-CD3 mAb for at least 5 h at 37°C. At the end of incubation, 
the wells were rinsed once with RPMI-1640 medium. A total of 
5 × 104 CD4+ T cells/well/500 μl were stimulated in serum-free 
X-VIVO 15 medium with soluble anti-CD28 mAb (1.0 μg/ml) in 
presence of cytokines including acid-treated TGF-β1 (5 ng/ml), 
IL-21 (25 ng/ml) for naïve T cells, and IL-1β (12.5 ng/ml) and IL-6 
(25 ng/ml) for memory T cells (18). Indicated concentrations of 
IgA, F(ab′)2 fragments of IgA, IVIG, or HSA were added to the 
cells 12 h after the initiation of culture. The cells were cultured for 
6 days at 37°C in 5% CO2. The supernatants were collected at the 
end of experiments for cytokine analysis and the cells were used 
for intracellular staining.
intracellular staining for cD4+  
T cells and cytokine assays
Cells were stimulated with phorbol 12-myristate 13-acetate 
(50 ng/ml, Sigma-Aldrich, Saint Quentin Fallavier, France) and 
ionomycin (500  ng/ml, Sigma-Aldrich) at 37°C for 6  h with 
GolgiStop (BD Biosciences Le Pont de Claix, France) for the last 
3 h. Cells were surface stained with BV421-conjugated CD4 mAb 
(clone RPA-T4, BD Biosciences). Cells were fixed, permeabilized 
(Fix/Perm, eBioscience, Paris, France), and incubated with 
APC-conjugated anti-human Foxp3 (clone 236A/E7, eBiosci-
ence), PE-conjugated anti-human IL-17A (clone eBio64CAP17, 
eBioscience), and FITC-conjugated anti-human IFN-γ (Clone 
4S.B3, BD Biosciences) at 4°C. Ten thousand cells were acquired 
for each sample and data were analyzed by using FACS DIVA and 
Flowjo softwares.
Intracellular staining for the phosphorylated STAT3 (pSTAT3) 
was carried out on stimulated CD4+ T  cells at indicated time 
points. Cells were harvested and fixed in pre-warmed BD 
Cytofix buffer by incubation for 10 min at 37°C. The cells were 
washed twice with staining buffer (1% fetal calf serum/PBS), 
permeabilized with chilled BD Phosflow Perm Buffer III on ice 
for 30 min. At the end of incubation, the cells were washed twice 
with staining buffer, incubated with PE-conjugated anti-STAT3 
pY705 (clone 4/P-STAT3, BD Biosciences) at room temperature 
for 45–60 min. Cells were washed and resuspended in staining 
buffer before acquisition.
Amounts of IL-17A in the cell-free supernatants were quanti-
fied by ELISA (DuoSet ELISA kit, R&D Systems).
analysis of expression of cD89  
and Dc-sign
CD4+ T  cells were stimulated with anti-CD3 and anti-CD28 
mAbs for 24 h. Cells were surface stained with BV421-conjugated 
CD4 mAb and APC-conjugated CD89 (clone A59, BioLegend, 
London, UK) or FITC-conjugated DC-SIGN (clone DCN46, BD 
Biosciences) mAbs for 30 min at 4°C. Monocytes were stained 
with FITC-conjugated HLA-DR (clone TU36, BD Biosciences) 
and APC-conjugated CD89, while DCs were stained with 
APC-conjugated HLA-DR (clone G46-6, BD Biosciences) and 
FITC-conjugated DC-SIGN mAbs. The expression of markers 
was analyzed by flow cytometry.
iga- and igg (iVig)-Binding assay
Total CD4+ T  cells were stimulated with anti-CD3/CD28 
mAbs for 24 hrs. To analyze the binding of IgA or IgG (IVIG) 
to CD4+ T  cells, either resting or anti-CD3, anti-CD28-
stimulated T  cells were incubated with BV421-conjugated 
anti-human CD4, FITC-conjugated CD45RA (clone HI100, BD 
Biosciences), and BV510-conjugated CD45RO (clone UCHL1, 
BD Biosciences) antibodies and DyLight 650-conjugated-IgA 
or IgG (IVIG) (3 μg/106 cells) for 30 min. Cells were analyzed 
by flow cytometry.
Immunoglobulin A and IgG binding to IL-1RI and IL-6Rα was 
measured by ELISA. ELISA plates were coated with recombinant 
IL-1RI (human IL-1Ra, expressed in 293E cells) and IL-6Rα 
(human IL-6Rα, expressed in insect cells) (1 μg/ml) (BioLegend) 
overnight at 4°C. After blocking with 5% BSA in PBS, 0.02% 
Tween 20 for 1 h at 37°C, wells were incubated with different con-
centrations of IgA, or IVIG for 2 h at 37°C. Following washings, 
the plates were incubated with horseradish peroxidase-labeled 
anti-human IgA or IgG for 2 h, followed by development with 
3,3′,5,5′-tetramethylbenzidine. The absorbance was measured 
at 450 and 570 nm. The data were analyzed by subtracting the 
absorbance of 570 nm from those of 450 nm.
statistical analysis
The data were analyzed by one-way ANOVA (repeated measures 
with Tukey’s multiple comparison test) or two-tailed Student’s 
t-test using GraphPad Prism software.
resUlTs
miga inhibits Differentiation of human 
Th17 cells
CD45RA+CD25− naïve CD4+ T cells were stimulated with anti-
CD3 and anti-CD28 mAbs in the presence TGF-β and IL-21 for 
6 days to differentiate Th17 cells. TGF-β is required to induce 
both FoxP3 and RORC in naïve T  cells and to inhibit IFN-γ 
while IL-21 relives RORC from the FoxP3 by inducing STAT3 
activation (2, 18). Twelve hours after the initiation of culture, 
mIgA was added to the cells at various concentrations (5, 15, 
and 25 mg/ml). We observed that mIgA significantly inhibits the 
differentiation of human Th17 cells (Figures 1A,B) as analyzed 
by intracellular staining for IL-17A. Significant inhibitory effect 
was observed even at low concentrations (5  mg/ml) of mIgA. 
In addition, mIgA also inhibited the production of IL-17A, the 
signature cytokine of Th17  cells (Figure  1C). The suppressive 
effect of mIgA was similar to that of therapeutic intravenous 
immunoglobulin IgG (IVIG) (Figures 1A–C) that is used in the 
therapy of various autoimmune, inflammatory, and infectious 
diseases (19–23) and was previously shown to inhibit Th17 
responses both in experimental models and in patients with 
autoimmune diseases (24–29).
The effect of mIgA on the inhibition of Th17 differen-
tiation was specific, as equimolar concentration of HSA (10 mg, 
FigUre 1 | Monomeric iga (miga) inhibits differentiation of human Th17 cells and affects the generation of iFn-γ+cD4+ T cells under Th17 
differentiation conditions without modulating FoxP3+ T cells. (a) Flow cytometry analysis of intracellular IL-17A in the naïve CD4+ T cells cultured in 
serum-free X-vivo medium in the presence of anti-CD3 and anti-CD28 mAbs alone (medium) or stimulated with TGFβ and IL-21 for 6 days. mIgA (25 mg/ml), 
IVIG (25 mg/ml), or human serum albumin (HSA) (10 mg/ml) (0.15mM) were added to the T cell cultures after 12 h of cytokine stimulation. Data from one of five 
independent experiments are presented. (B) Percentage of IL-17A+CD4+ T cells (mean ± SEM, n = 5 donors) and (c) amount of secreted IL-17A (mean ± SEM, 
n = 9 donors) in T cell cultures differentiated under above conditions. mIgA was added at three different concentrations (5, 15, and 25 mg/ml). (D) Flow 
cytometry analysis of intracellular IFN-γ in the naïve CD4+ T cells under Th17 differentiation conditions. Data from one of five independent experiments are 
presented. (e) Percentage of IFN-γ+CD4+ T cells and (F) CD4+CD25+FoxP3+ T cells (mean ± SEM, n = 5 donors) among CD4+ T cells cultured under above 
conditions. Statistical significance as determined by one-way ANOVA is indicated (*P < 0.05; ***P < 0.001; ns, not significant).
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0.15 mM), used as protein control, did not alter Th17 differentia-
tion (Figures 1A–C). Also, the inhibitory effect of mIgA on Th17 
responses was not due to toxic effects of the immunoglobulins 
as we did not observe differences in the yield of cells in mIgA-
treated conditions as compared to cytokine-treated control cells 
or HSA-treated cells.
We also analyzed the effect of mIgA on frequency of IFN-
γ-secreting CD4+ T  cells in the culture. We found that mIgA 
was equally effective to inhibit IFN-γ responses under Th17 
differentiation conditions (Figures 1D,E). Further, similar to our 
previous report on IVIG (24), inhibition of Th17 differentiation 
by mIgA was not associated with the reciprocal enhancement 
of CD4+CD25high FoxP3+ Tregs (Figure 1F). Thus, these results 
demonstrate that mIgA exhibits inhibitory effects on the differ-
entiation of human Th17 cells.
miga suppresses amplification  
of human Th17 cells
For the amplification of human Th17 cells, CD45RO+ memory 
CD4+ T  cells were stimulated with anti-CD3 and anti-CD28 
mAbs in the presence of IL-1β and IL-6 for 6  days. By sign-
aling through corresponding cytokine receptors, IL-1β and 
IL-6 induce phosphorylation of STAT3 and amplify Th17 cells 
in the memory CD4+ T cell pool (2, 18). Similar to Th17 cell 
differentiation conditions, various concentrations of mIgA (5, 
15, and 25 mg/ml) were added to the cells 12 h post initiation 
of culture. The pro-inflammatory cytokines IL-1β and IL-6 
significantly enhanced the frequency of IL-17A-producing cells 
as compared to memory CD4+ T  cells stimulated with anti-
CD3 and anti-CD28 mAbs alone (Figures 2A,B). Remarkably, 
mIgA significantly suppressed the amplification of Th17  cells 
(Figures  2A,B) and the amount of IL-17A (Figure  2C) pro-
duced by these cells. Its inhibitory effect was similar to that 
of high-dose IVIG (Figures  2A–C). Of note, the inhibitory 
effect of mIgA on IFN-γ responses under Th17 amplification 
conditions was observed only at the highest immunoglobulin 
concentration (Figure 2D).
Under Th17 amplification conditions, the inhibitory effect of 
mIgA on Th17 cells was associated with a reciprocal enhancement 
of FoxP3+ Tregs (Figure 2E). The effect of mIgA on Tregs was 
prominent at the highest concentration (25 mg/ml). These results 
thus suggest that both mIgA and IVIG exert similar modulatory 
effects on Th17 amplification.
Fcαri (cD89) and Dc-sign are 
Dispensable for the inhibition of 
Th17 response by miga
Recent reports have indicated that FcαRI (CD89) plays a major 
role in mediating anti-inflammatory effects of mIgA on innate 
immune cells (10–13, 16). In addition, SIGN-R1 on DCs was 
also implicated in the immunoregulatory functions of secretory 
IgA (30). To explore if FcαRI and DC-SIGN (human counterpart 
of SIGN-R1) receptors are implicated in the inhibitory effect of 
mIgA, we investigated the expression of these two receptors on 
activated CD4+ T cells. We found that human CD4+ T cells were 
negative for both, FcαRI and DC-SIGN (Figures  3A,B), thus 
ruling out their implication in the inhibition of Th17 responses by 
mIgA. Importantly, monocytes and DCs that were used as posi-
tive controls stained with specific anti-FcαRI and anti-DC-SIGN 
fluorescent antibodies, respectively (Figures 3A,B).
inhibition of Th17 response by miga 
implicates F(ab′)2 Fragments
Lack of expression of FcαRI and DC-SIGN on CD4+ T  cells 
raised an important prospect that suppressive effects of mIgA 
on Th17 cell responses might be mediated via F(ab′)2 fragments. 
Indeed, we found that F(ab′)2 fragments of mIgA significantly 
inhibited the frequency of IL-17A-positive T  cells under Th17 
differentiation conditions (Figure  3C). This effect was also 
associated with significant downregulation of IFN-γ-secreting 
CD4+T cells in the culture (Figure 3D).
miga Binds to cD4+ T cells
Natural antibodies that recognize various self-motifs have 
been identified (31–34). Therefore, to further understand the 
mechanisms underlying the inhibitory effect of IgA on Th17 
responses, we analyzed the binding of mIgA to CD4+ T  cells 
by flow cytometry. We found that nearly 45% of the stimulated 
CD4+ T  cells (n =  9 donors) were positive for mIgA binding 
(Figures  4A,B). mIgA however did not bind to resting CD4+ 
T cells (n = 3 donors) suggesting that activation signals license 
T  cells for immunoglobulin binding. Further, the extent of 
binding of mIgA was similar for CD45RA+ naïve and CD45RO+ 
memory CD4+ T cells (Figures 4C,D). This finding indicates that 
naturally occurring mIgA exerts its immunomodulatory effects 
by binding to CD4+ T cells.
miga and iVig recognize cD4+ T cells to 
a similar extent
As both mIgA and IVIG reciprocally regulated Th17 and Tregs 
at equivalent concentration, rises the possibility that they 
recognize CD4+ T  cells to a similar extent. Confirming our 
proposition, we observed that both immunoglobulin fractions 
bind CD4+ T cells to a similar magnitude (Figures 5A–C). To 
further substantiate these results, we investigated the surface 
molecules on CD4+ T cells that could be recognized by mIgA 
and IVIG. As mIgA and IVIG inhibited cytokine-mediated 
Th17 differentiation and amplification, we hypothesized that 
the corresponding cytokine receptors on CD4+ T  cells are 
the targets for these immunoglobulin fractions. Therefore, we 
analyzed binding of mIgA and IVIG to IL-6Rα and IL-1RI, the 
receptors for IL-6 and IL-1β that are implicated in the amplifica-
tion of Th17 cells (1, 2, 18, 35). mIgA recognized both IL-6Rα 
and IL-1RI in a dose-dependent manner (Figures  5D,E). The 
binding of mIgA was however stronger for IL-6Rα. Importantly, 
IVIG and mIgA showed similar pattern of recognition of IL-6Rα 
and IL-1RI (Figures 5D,E).
miga interferes with sTaT3 activation
STAT3 has a key role in the Th17 cell programming by reliev-
ing RORC from FoxP3-mediated inhibition. Together with 
RORC, it facilitates the secretion of effector cytokines of 
FigUre 2 | Monomeric iga (miga) reciprocally regulates Th17 cells and FoxP3+ T cells under Th17 amplification conditions. (a) Flow cytometry 
analysis of intracellular IL-17A in the memory CD4+ T cells cultured in serum-free X-vivo medium in the presence of anti-CD3 and anti-CD28 mAbs alone 
(medium) or stimulated with IL-6 and IL-1β for 6 days. mIgA (25 mg/ml), IVIG (25 mg/ml), or human serum albumin (HSA) (10 mg/ml) (0.15mM) were added to the 
T cell cultures after 12 h of cytokine stimulation. Data from one of five independent experiments are presented. (B) Percentage of IL-17A+CD4+ T cells 
(mean ± SEM, n = 5 donors) and (c) amount of secreted IL-17A (mean ± SEM, n = 9 donors) in T cells cultured under above conditions. mIgA was added at 
three different concentrations (5, 15, and 25 mg/ml). (D) Percentage of IFN-γ+CD4+ T cells (mean ± SEM, n = 5 donors) and (e) CD4+CD25+FoxP3+ T cells 
(mean ± SEM, n = 5 donors) among CD4+ T cells cultured under above conditions. Statistical significance as determined by one-way ANOVA is indicated 
(*P < 0.05, **P < 0.01, ***P < 0.001).
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Th17  cells. STAT3 is activated by Th17-polarizing cytokines 
(1, 2). As we found that mIgA recognizes cytokine receptors 
implicated in Th17 responses, we aimed at exploring if this 
binding of mIgA on CD4+ T cells has a repercussion on STAT3 
phosphorylation and hence interferes with early signaling 
events of Th17 cells. In line with our proposition, we uncov-
ered that mIgA significantly suppresses the phosphorylation of 
STAT3 at Y705 both in Th17 differentiation and amplification 
conditions (Figures 6A–E).
DiscUssiOn
Patients with selective IgA deficiency not only exhibit 
enhanced predisposition to mucosal infections but also to 
FigUre 3 | inhibition of Th17 response by monomeric iga (miga) implicates F(ab′)2 fragments while cD89 and Dc-sign are dispensable. (a,B) 
Flow cytometric analysis human CD4+ T cells, monocytes, and dendritic cells for the expression of CD89 and DC-SIGN. (c,D) Percentage of (c) IL-17A+CD4+ 
T cells and (D) IFN-γ+CD4+ T cells (mean ± SEM, n = 4 donors) in T cells cultured in serum-free X-vivo medium in the presence of anti-CD3 and anti-CD28 
mAbs alone (Medium) or stimulated with TGFβ and IL-21 for 6 days. mIgA (25 mg/ml), F(ab′)2 fragments of mIgA (15 mg/ml), or human serum albumin (HSA) 
(10 mg/ml) (0.15mM) were added to the T cell cultures after 12 h of cytokine stimulation. Statistical significance as determined by one-way ANOVA is indicated 
(*P < 0.05; **P < 0.01).
7
Saha et al. Modulation of Human Th17 Response by mIgA
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 275
several autoimmune and allergic conditions including arthritis, 
autoimmune endocrinopathies, and intestinal inflammatory 
diseases such as ulcerative colitis and Crohn’s disease (36). 
These observations support the role of IgA in the immune 
regulation and homeostasis. The immunoregulatory functions 
of IgA are mediated mainly via FcαRI, expressed on various 
innate immune cells. Whether such an interaction is inflamma-
tory or anti-inflammatory is determined by nature of the IgA. 
Thus, IgA immune complexes and polymeric IgA were reported 
to induce activation of innate immune cells while mIgA was 
found to be anti-inflammatory. The anti-inflammatory effects of 
mIgA include its inhibitory effect on the chemotaxis of immune 
FigUre 4 | Monomeric iga (miga) binds to cD4+ T cells. (a,B) Representative dot plots and percentage (mean ± SEM, n = 3–9 donors) of binding of 
DyLight650-conjugated mIgA to CD4+ T cells. Statistical significance as determined by two-tailed Student’s t-test is indicated (**P < 0.01). (c,D) Representative dot 
plots and percentage (mean ± SEM, n = 4) of binding of DyLight650-conjugated mIgA to CD4+ T cells, CD4+CD45RA+ naïve T cells, and CD4+CD45RO+ memory 
T cells. Statistical significance as determined by one-way ANOVA is indicated (**P < 0.01; ***P < 0.001; ns, not significant).
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cells, IgG-mediated phagocytosis and bactericidal activity 
of polymorphonuclear cells, and secretion of inflammatory 
cytokines such as TNF and IL-6 (37–43). Furthermore, mIgA 
also induces the production of IL-10 by human monocytes and 
monocyte-derived DCs (44). Of note, recognition of secretory 
IgA via carbohydrate-recognizing receptors on innate cells such 
as SIGN-R1 has also been suggested (30, 45, 46). This interaction 
rendered DC tolerogenic characterized by the secretion of IL-10 
and gaining the ability to expand Tregs. Our current results show 
that mIgA exerts direct anti-inflammatory functions on effector 
T cells, independent of FcαRI, DC-SIGN, and innate cells. These 
data thus further expand the landscape of immunoregulatory 
functions of IgA and of natural immunoglobulins.
Aberrant activation of Th17 cells and their effector cytokines 
IL-17A and GM-CSF are implicated in the pathogenesis of various 
autoimmune and inflammatory diseases such as systemic lupus 
erythematosus, rheumatoid arthritis, psoriasis, dermatomyosi-
tis, allergy, asthma, and others (2). Importantly, targeting Th17 
responses have given promising results in experimental models 
of autoimmune diseases and in patients (47). Recent data from 
ours and others show that beneficial effects of therapeutic IVIG 
containing IgG from pooled plasma of thousands of healthy 
FigUre 5 | Monomeric iga (miga) and iVig recognize cD4+ T cells and cytokine receptors to a similar extent. (a–c) Representative dot plots, 
percentage (mean ± SEM, n = 4), and intensity (mean ± SEM, n = 4) of binding [as shown by median fluorescence intensity (MFI)] of DyLight650-conjugated mIgA 
and IVIG to CD4+ T cells. (D,e) Binding of mIgA and IVIG to recombinant IL-6Rα and IL-1RI as analyzed by ELISA. Immunoglobulins were tested at serial 
concentrations (1–0.002 mg/ml). Statistical significance as determined by one-way ANOVA is indicated (***P < 0.001; ns, not significant).
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donors is associated with inhibition of Th17 responses (24–29, 
48–50), indicating that immunoglobulins have regulatory func-
tions on Th17 cells. The data from current report show that in 
addition to IgG, mIgA also exerts modulatory effects on Th17 
responses. In fact, mIgA was recently demonstrated to attenuate 
experimental arthritis in human CD89 transgenic mice (11), a 
disease where Th17 cells have a key role in the pathogenesis. It 
should be noted that the serum levels of IgA ranges from 2 to 
3 mg/ml, but we observed consistent inhibitory effect of mIgA 
both on differentiation and amplification of Th17 cells at higher 
doses (25 mg) and was analogous to what is observed with IVIG 
(24). The lower concentration of mIgA (5 mg) although shown 
inhibitory effects on Th17 differentiation, significant effects 
were not observed on all parameters of Th17 amplification. 
Immunoglobulins exert their anti-inflammatory effects via 
several mutually non-excusive mechanisms and it might explain 
requisite of higher concentrations of immunoglobulins for the 
therapeutic purposes to inhibit inflammation.
Recent reports show that Th17  cells are required for the 
production of high affinity secretory IgA at intestinal mucosal 
FigUre 6 | Monomeric iga (miga) interferes with signal transducer and activator of transcription 3 (sTaT3) activation. CD4+ T cells were cultured in 
serum-free X-vivo medium in the presence of anti-CD3 and anti-CD28 mAbs alone (medium) or stimulated with cytokines for the differentiation of Th17 cells 
[TGFβ and IL-21, panels (a–c)] or for the amplification of Th17 cells [IL-1β and IL-6, panels (D,e)]. mIgA (25 mg/ml) or human serum albumin (HSA) (10 mg/ml) 
(0.15 mM) were added to the T cell cultures. Phosphorylation of STAT3 was analyzed after 72 h. (a) Representative histograms showing pSTAT3 in different 
experimental conditions for differentiating Th17 cells. (B–e) Percentage of pSTAT3+CD4+ T cells (B,D) and median fluorescence intensity (MFI) of pSTAT3 (c,e) 
under Th17 differentiation (B,c) (mean ± SEM, n = 5 donors) and amplification (D,e) (mean ± SEM, n = 5 donors) conditions. Statistical significance as 
determined by one-way ANOVA is indicated (*P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant).
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surfaces (51, 52). Payer patch-homing Th17  cells induce IgA-
producing germinal center B  cells by acquiring the phenotype 
of follicular T cells and producing IL-21. A similar mechanism 
was also reported for the promotion of local IgA responses in 
lungs by vaccine-induced Th17 cells (53). Thus, Th17 cells and 
secretory IgA work in cooperation to protect mucosal surfaces 
against microbial invasion and regulating the microbiota. 
Although Th17 cells were reported to provide help for B cells to 
produce systemic IgG response via IL-21 and IL-17 (54), their 
role for circulating IgA response is not known. As we uncovered 
that mIgA inhibits Th17 responses, these data together suggest 
that under the conditions where Th17 cells are hyperactivated, 
IgA has the ability to control its own helpers to keep the immune 
response at check.
Natural antibodies (immunoglobulins) that are produced 
in the absence of deliberate immunization and independent of 
external antigens constitute an integral part of immunoglobulin 
repertoire (55–64). A major fraction of these natural antibodies 
recognize self-motifs and are termed as natural autoantibodies. 
These natural autoantibodies have important role in the therapeu-
tic benefits of IVIG in autoimmune and inflammatory conditions 
(23, 31, 65). Our results indicate that inhibitory effect of mIgA on 
Th17 cells is mediated in part via natural IgA autoantibodies that 
recognize cytokine receptors on CD4+ T cells and interfere with 
Th17 programming. In fact, we found that both mIgA and IVIG 
recognize CD4+ T cells as well as IL-6Rα and IL-1RI to a similar 
extent. Also, significant downregulation of STAT3 phosphoryla-
tion by mIgA support our proposition.
Although we found that mIgA directly inhibits Th17 responses 
independent of FcαRI and DC-SIGN, we believe that the effect 
of mIgA on Th17 cells in vivo also implicates innate cells such as 
DCs, monocytes, and macrophages, which are known to provide 
signals for Th17 responses (2). In fact, several reports have now 
shown that mIgA exerts FcαRI-mediated anti-inflammatory 
effects on innate cells by prompting ITAMi configuration (10–13, 
16). It should be noted that IVIG (IgG) and IgA display distinct 
differences in their glycosylation pattern. IgG is glycosylated at 
Asn297 of the Fc-fragment and about 15–25% of IgG are gly-
cosylated at the Fab region (66). IgA on the other hand is the 
most glycosylated form of immunoglobulin and over 6% of IgA 
content are represented by sugars (67). In addition to N-linked 
glycans at asparagine 263 and asparagine 459 of Fc region, up to 
five O-linked glycan chains containing of N-acetylgalactosamine 
with β1,3-linked galactose and sialic acids can be found at the 
hinge region serine and threonine residues of IgA1, the pre-
dominant IgA subclass in the circulation (68, 69). Similar to 
IgG, about 30% of Fab fragments of IgA1 also contain N-linked 
glycans (69). Further, IgA1 and IgG display significant differences 
in the sialylation content of N-glycans. In contrast to IgG that 
contains sialic acid in less than 10% N-glycans, nearly 90% of the 
N-glycans in IgA1 are sialylated mainly with α2,6-configuration 
(69). Whether differences in the glycosylation patterns of IgA and 
IgG impact modulation of innate cells and innate cell-mediated 
Th17 responses remains to be investigated. Due to heterogeneous 
composition of glycan chains, further work is also necessary with 
mIgA preparations containing defined glycosylation patterns 
to finely dissect the role of IgA in modulating Th17 responses. 
Since F(ab′)2 fragments of mIgA could inhibit Th17 responses 
similar to intact mIgA and that F(ab′)2 fragments of IVIG were 
previously reported to inhibit Th17 responses both in vitro and 
in vivo (24, 70) imply that N-linked glycans (and hence sialyla-
tion) at Fc region of mIgA might not have a role in regulating 
Th17 responses.
In conclusion, our data highlight the promise of plasma-
derived mIgA as therapeutic molecule for autoimmune and 
inflammatory diseases and hence represents an innovative 
plasma-derived therapeutic product (71). Although shorter 
half-life of IgA as compared to IgG is the major drawback, the 
efficacy of mIgA on Th17 cells should instigate the therapeutic 
development of monomeric plasma IgA as an analog to IVIG.
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